M. Andreeff

Publications1,538
h-index125
Citations59,955
Highly Influential Citations1,759
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Kantarjian
  • 4,760 Publications • 212,147 Citations
  • M. Konopleva
  • 1,428 Publications • 34,930 Citations
  • J. Cortes
  • 3,046 Publications • 104,058 Citations
  • F. Ravandi
  • 1,714 Publications • 37,084 Citations
  • Publications
  • Influence
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
TLDR
ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells, suggesting that ABT- 737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered. Expand
Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression
TLDR
Evidence is provided that TAF are derived from mesenchymal stem cells that acquire a TAF phenotype following exposure to or systemic recruitment into adenocarcinoma xenograft models including breast, pancreatic, and ovarian and under long-term tumor conditioning in vitro, MSC express TAF–like proteins. Expand
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
TLDR
It is demonstrated that, for the purpose of anticancer therapy, bone marrow-derived mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites and that the tumor microenvironment preferentially promotes the engraftment of MSCs as compared with other tissues. Expand
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
TLDR
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy. Expand
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
TLDR
Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival. Expand
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
TLDR
Novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds are provided. Expand
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
TLDR
It is concluded that hMSCs can integrate into human gliomas after intravascular or local delivery, that this engraftment may be mediated by growth factors, and that this tropism of hMSC for human gl iomas can be exploited to therapeutic advantage. Expand
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
TLDR
Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis. Expand
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
TLDR
It is concluded that miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations, and a small subset of miRNAs is correlated with survival. Expand
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
TLDR
Injected MSC-IFN-beta cells suppressed the growth of pulmonary metastases, presumably through the local production of IFN- beta in the tumor microenvironment, and may be an effective platform for the targeted delivery of therapeutic proteins to cancer sites. Expand
...
1
2
3
4
5
...